At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antiplatelets; Prostaglandins; Small molecules
- Mechanism of Action Prostaglandin D agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Coronary disorders; Thrombosis
Most Recent Events
- 16 Jan 1996 Discontinued-I for Coronary disorders in United Kingdom (Unknown route)
- 04 May 1995 Discontinued-I for Thrombosis in United Kingdom (Unknown route)